News From The Journal Of Clinical Investigation: March 8, 2010
Warning sign for potential anticancer approach One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. For example, the TLR7 stimulant imiquimod is used for the treatment of skin cancer and metastatic melanoma…
Read Full Article
News From The Journal Of Clinical Investigation: March 8, 2010
Warning sign for potential anticancer approach One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. For example, the TLR7 stimulant imiquimod is used for the treatment of skin cancer and metastatic melanoma…
Read Full Article
2nd European Lung Cancer Conference
Rapid advances in drug development, genetics and multidisciplinary treatment have brought the field of oncology to a critical moment, says Dr. Rafael Rosell from the Catalan Institute of Oncology in Badalona, Spain, co-chair of the second European Lung Cancer Conference (ELCC), which will be held in Geneva, Switzerland from 28 April to 1 May 2010…
Read Full Article
Prolonged Use Of HRT Increases Incidence Of Lung Cancer By About 50 Percent: New Study
Women aged 50 to 76 who take estrogen plus progestin may have an increased risk of lung cancer, according to a new study published in the pre-print online edition of the Journal of Clinical Oncology…
Read Full Article
The Effects Of Patient Attitudes On Patient Outcomes
Research published in the March edition of the Journal of Thoracic Oncology (JTO) explored the importance of a patient’s outlook as it relates to health behavior and health status. Researchers focused on lung cancer patients and discovered that those who exhibited an optimistic disposition experienced more favorable outcomes than those with a pessimistic disposition…
Read Full Article
‘Salvage’ Therapy Just As Suitable For NSCLC Patients Over Age 70 As For Younger Patients
Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy…
Read Full Article
Synta Presents STA-9090 NSCLC Data At The IASLC 10th Annual Targeted Therapies Of The Treatment Of Lung Cancer Meeting
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I…
Read Full Article
Novelos Therapeutics Pivotal Phase 3 Lung Cancer Trial Does Not Meet The Primary Survival Endpoint
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy…
Read...
BSD Medical Reports Publication Of Chinese Study Using The BSD-2000 Hyperthermia System To Treat Lung Cancer
BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132-135) by Yang, Zhao, and Wang…
Read Full Article
Lilly, Merck, And Pfizer Join Forces To Accelerate Research And Improve Treatment Of Lung And Gastric Cancers In Asia
Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia…
Read Full Article
Translator
Copyright © 2009 The Cancer Foundation For The World Inc. A registered 501(c)3 Non-Profit public charity. || Privacvy Policy || Disclaimer